Clinical characteristics of patients with NLPHL, NLPHL with T-cell/histiocyte-rich nodules, and T/HRBCL
Diagnosis . | NLPHL . | P . | NLPHL with T-cell/histiocyte-rich nodules . | P . | T/HRBCL . | P, NLPHL vs T/HRBCL . |
|---|---|---|---|---|---|---|
| No. cases | 53 | NS | 17 | NS | 35 | .006 |
| Age, years | 39 | NS | 41 | NS | 49 | < .01 |
| Hemoglobin level, g/L | 142 | NS | 137 | NS | 136 | NS |
| Tumor diameter, cm | 5 | NS | 7 | NS | 7 | NS |
| LDH level, U/L | 205 | NS | 190 | NS | 284 | NS |
| Sex, % male | 68 | < .05 | 94 | NS | 74 | NS |
| Stage, %* | ||||||
| I | 43 | < .005 | 20 | NS | 23 | < .005 |
| II | 37 | < .005 | 20 | NS | 29 | < .005 |
| III | 20 | < .005 | 27 | NS | 26 | < .005 |
| IV | 0 | < .005 | 33 | NS | 22 | < .005 |
| B symptoms, % | 5 | < .001 | 38 | NS | 46 | < .001 |
| Treatment, %* | ||||||
| Surgery only | 6 | .09 | 0 | .05 | 0 | < .001 |
| RTx only | 22 | .09 | 15 | .05 | 8 | < .001 |
| COPP/ABVD | 34 | .09 | 15 | .05 | 24 | < .001 |
| BEACOPP | 30 | .09 | 39 | .05 | 8 | < .001 |
| CHOP based | 4 | .09 | 23 | .05 | 60 | < .001 |
| High dose | 0 | .09 | 8 | .05 | 0 | < .001 |
| Other | 4 | .09 | 0 | .05 | 0 | < .001 |
Diagnosis . | NLPHL . | P . | NLPHL with T-cell/histiocyte-rich nodules . | P . | T/HRBCL . | P, NLPHL vs T/HRBCL . |
|---|---|---|---|---|---|---|
| No. cases | 53 | NS | 17 | NS | 35 | .006 |
| Age, years | 39 | NS | 41 | NS | 49 | < .01 |
| Hemoglobin level, g/L | 142 | NS | 137 | NS | 136 | NS |
| Tumor diameter, cm | 5 | NS | 7 | NS | 7 | NS |
| LDH level, U/L | 205 | NS | 190 | NS | 284 | NS |
| Sex, % male | 68 | < .05 | 94 | NS | 74 | NS |
| Stage, %* | ||||||
| I | 43 | < .005 | 20 | NS | 23 | < .005 |
| II | 37 | < .005 | 20 | NS | 29 | < .005 |
| III | 20 | < .005 | 27 | NS | 26 | < .005 |
| IV | 0 | < .005 | 33 | NS | 22 | < .005 |
| B symptoms, % | 5 | < .001 | 38 | NS | 46 | < .001 |
| Treatment, %* | ||||||
| Surgery only | 6 | .09 | 0 | .05 | 0 | < .001 |
| RTx only | 22 | .09 | 15 | .05 | 8 | < .001 |
| COPP/ABVD | 34 | .09 | 15 | .05 | 24 | < .001 |
| BEACOPP | 30 | .09 | 39 | .05 | 8 | < .001 |
| CHOP based | 4 | .09 | 23 | .05 | 60 | < .001 |
| High dose | 0 | .09 | 8 | .05 | 0 | < .001 |
| Other | 4 | .09 | 0 | .05 | 0 | < .001 |
P values are given only when the difference is statistically significant (<.05). LDH indicates lactate dehydrogenase; RTx, radiotherapy; COPP, cyclophosphamide vincristine, procarbazine, and prednisone; ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; BEACOPP, bleomycine, etoposide, doxorubicin, and COPP; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone.
RTx only was given only to patients presenting with stage I disease; high dose indicates high-dose therapy with autologous stem cell transplantation.